EGFR and breast carcinoma: Of interest, some of these targeted drugs are more effective against the genetically altered cancerous form of the target, as illustrated by the activities of gefitinib and erlotinib against the mutated EGFR present in NSCLC [33,34], and the activity of trastuzumab against breast cancer with amplified ErbB2 [35].